CAR-T cell therapy in rheumatic diseases: a review article
Clinical Rheumatology · 2026-02 · 45 (2) · 637-650
DOI: 10.1007/s10067-025-07451-7 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Rheumatology, online erschienen am 26.04.2025. Verfasst von Harshwardhan Patil und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, JSS College of Pharmacy, Mysuru, India. Hauptthemen laut MEDLINE: Rheumatic Diseases, Immunotherapy, Adoptive, Receptors, Chimeric Antigen, T-Lymphocytes. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 75 Literaturangaben.
Abstract (Originalsprache)
CAR-T cell therapy, a pioneering immune-modulating treatment that was initially designed for hematologic malignancies, is now being considered a potential treatment for autoimmune and rheumatic diseases. This method involves genetically engineering T cells to express chimeric antigen receptors (CARs), allowing them to target specific antigens associated with pathogenic immune cells. The review covers the possibility of CAR-T therapy in the treatment of autoimmune diseases like systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc). The therapy's ability to maintain remission by targeting autoreactive B cells in the course of disease has been an important aspect of studies involving SLE. In refractory RA, CAR-T cells also demonstrate a potential therapeutic modality in selectively killing immune cells driving the disease process. For SSc, CAR-T therapy may represent a novel therapeutic approach because it targets the dysregulated activity of B cells as well as the fibrotic processes that drive the disease pathology. Emerging evidence suggests potential applications in conditions such as Sjögren's syndrome and dermatomyositis. While CAR-T therapy promises accuracy, persistence, and the potential for long-term remission, many problems remain, including the risk of cytokine release syndrome, immune toxicity, and treatment affordability. The development of CAR-Tregs and advanced gene-editing techniques may increase the specificity and safety of therapy. In addition, clinical trials and long-term studies should be conducted to establish the efficacy, safety, and economic feasibility of this innovative approach. This review underscores the transformative potential of CAR-T therapy in the management of rheumatic diseases, particularly in refractory cases. Offering targeted immunomodulation with a minimum of systemic immune suppression, CAR-T therapy could redefine therapeutic paradigms and offer hope for improved outcomes in autoimmune diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Practice, JSS College of Pharmacy, Mysuru, India.
- JSS Medical College, Mysuru, India.
- Department of Clinical Immunology and Rheumatology, JSS Medical College, JSS Academy of Higher Education and Research, Mysuru, India.
- Department of Clinical Immunology and Rheumatology, JSS Medical College, JSS Academy of Higher Education and Research, Mysuru, India. mahabaleshwarm@jssuni.edu.in.
Zitieren
APA
Patil, H., Bharadwaj, R. K., Dutta, N., Subramanian, R., Prasad, S., & Mamadapur, M. (2026). CAR-T cell therapy in rheumatic diseases: a review article. Clinical Rheumatology, 45(2), 637-650. https://doi.org/10.1007/s10067-025-07451-7
Vancouver
Patil H, Bharadwaj RK, Dutta N, Subramanian R, Prasad S, Mamadapur M. CAR-T cell therapy in rheumatic diseases: a review article. Clinical Rheumatology. 2026;45(2):637-650. doi:10.1007/s10067-025-07451-7
BibTeX
@article{Patil2026,
author = {Patil, Harshwardhan and Bharadwaj, Rajath K and Dutta, Nilanjana and Subramanian, Ramaswamy and Prasad, Shiva and Mamadapur, Mahabaleshwar},
title = {CAR-T cell therapy in rheumatic diseases: a review article},
journal = {Clinical Rheumatology},
year = {2026},
volume = {45},
number = {2},
pages = {637--650},
doi = {10.1007/s10067-025-07451-7}
}
EUVIMED